/
Other
HER2 Positive
37
Pipeline Programs↗
46
Active Trials↗
38
Companies Involved↗
HER2 Positive is a moderately active landscape with 37 programs across 38 companies. The most active players are Xuanzhu Biopharmaceutical Co., Ltd.. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 17
Phase 212
Phase 37
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
28 of 35 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 97% of 37 pipeline programs.
Analysis
Trial Status
98
clinical trials
Completed25 · 26%
Recruiting24 · 24%
Active, not recruiting13 · 13%
Unknown status13 · 13%
Terminated8 · 8%
Not yet recruiting7 · 7%
Other8 · 8%
Clinical Trials
Trial Activity
98 trials
A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 3·NCT07043725·544 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)